Breakthrough. New insights into the treatment of sarcoidosis are leading to important clinical changes. Glucocorticosteroids, such as prednisone, are no longer automatically considered the first-line and only cornerstone of therapy. Instead, increasing attention is being given to a more personalized and patient-centered approach to care.
This paradigm shift reflects a growing awareness that treatment decisions should not focus solely on controlling inflammation, but also on minimizing side effects, preserving long-term health, and improving quality of life. Every patient with sarcoidosis is different, and treatment strategies should therefore be tailored to the individual patient’s needs, symptoms, daily functioning, and personal goals.
Patients are now being recognized as active partners in the treatment process, with more emphasis on shared decision-making and individualized care. This marks an important step toward truly personalized medicine in sarcoidosis.
Would you like to read the full article? Link
Figure: Approach to the treatment of sarcoidosis and strategies to reduce the use and duration of oral corticosteroids. Patients treated with oral corticosteroids should be evaluated every 1 to 3 months with the aim of tapering and, if possible, discontinuing this medication. TNF = tumor necrosis factor.